


¹Dept of Medicine, Div of Nephrology; ²Dept of Pathology and Cell Biology; ³Depts of Urology, Genetics & Development and Pathology
Columbia University Irving Medical Center, New York, NY

Results


Removal of Crkl exon 1 results in complete knockout, while selective ablation of exon 2 leads to a functional overexpression of Crkl T2



A-V: Dissection and H&E images taken from each cohort within the series of conditional deletions. **(A-C)** Removal of both *Crkl* splice variants from the MM yields severe phenotypes at the macro- and microscopic levels, including malformed glomeruli (C, yellow arrows), while removal of only T1 **(D-F)** also yields a severe phenotype, albeit with lower frequency. **(H-J)** Removal of both splice variants from both the MM and UB, or of only T1 **(K-M)** lead to upper and lower urinary tract defects, including hypoplasia, which was the most common phenotype in both groups. **(N-P)** Removal of both splice variants in the UB had no effect on phenotype, whereas removal of only T1 **(Q-S)** lead to dilations at the UPJ (R) in 30% of mice. **(T-V)** Age-matched wild-type. KA = Kidney anomaly, OU = Obstructive Uropathy. All images are from animals at 3 weeks gestation (18.5dpc - P0).



In a series of fluorescent RNAscope ISH assays, probes against *Six2*, *Hoxb7* and *Crkl* were tested on wild-type tissues at **(A)** 13.5 and 15.5dpc, and **(B)** in tissues from a global *Crkl* knockout. **(C)** A *Crkl* T2-specific BaseScope probe, targeting the *Ex1-Ex3 splice junction*, was used on tissues from 15.5dpc wild-type and global mutant mice, where there is an observed absence of T2 in *Crkl* (*Ex1*)^{-/-} mutants, but an *unexpected increase* in the expression of T2 in *Crkl* (*Ex2*)^{-/-} global mutants. **(D)** Sashimi plots of bulk RNAseq data show raw reads coverage within and across *Crkl* exons & junctions (resp.). Peaks indicate greater read coverage; curved lines represent coverage of exon-exon junctions. Note increased coverage of the Ex1-Ex3 splice junction (arrowheads) in *Six2-cre⁺;Crkl* (*Ex2*)^{fl/fl} mice, where only T2 can be expressed, indicating higher expression vs wild type or *Six2-cre⁺;Crkl* (*Ex1*)^{fl/fl} mutants.

Bulk RNA-seq coupled with supervised single cell deconvolution implicates Klotho-dependent Fgf signaling in SSB development



Differential expression analysis of bulk RNAseq data from **(A)** *Six2-cre⁺;Crkl (Ex1)^{fl/fl}*, and **(B)** *Six2-cre⁺;Crkl (Ex2)^{fl/fl}* at 15.5dpc show more dysregulated genes in the absence of T1 and T2 compared to the loss of only T1. **(C)** Deconvolution of bulk RNA-seq to pseudo scRNA-seq (Nagatsuma H., *et al.*, Dev Biol 2021 Feb;470:62-73) shows increase in genes expressed by the SSB-ePT-PT cell population in the *Six2-cre⁺;Crkl (Ex1)^{fl/fl}* mutant, and depletion of these genes in the *Six2-cre⁺;Crkl (Ex2)^{fl/fl}* mutant. **(D)** *Klotho* is uniquely expressed in this cell population and its mRNA is significantly and oppositely regulated across each genetic context

Loss of both Crkl isoforms leads to an overbranched phenotype, while genetic ablation of only T1 leads to developmental delay



Conclusions & Future Directions

- This study confirms the causal role of *CRKL* in kidney malformations observed in individuals with the Chr. 22q11.2 microdeletion syndrome and demonstrates the requirement of both *Crkl* isoforms for normal urinary tract development.
- By selectively ablating one or both transcripts, data imply a negative and positive, resp., effect on regulation of Klotho-dependent proliferation of S-shaped bodies / early proximal tubule cells during early development.
- Based on the literature, it is likely that Fgf signaling (i.e. Fgf8 and Fgf10) is dysregulated, starting from the *Six2*+ nephron progenitors where *Crkl* is genetically altered, providing a potential mechanism for the hypothesized Klotho-mediated branching phenotypes.
- Furthermore, Klotho-dependent Fgf signaling is likely to constitute a unifying cellular mechanism for the cardiac, craniofacial and urinary tract malformations related to genetic mutations in *CRKL*.

Funding

NIH/NIDDK P20 DK116191 (SSC), NIH/NIDDK R01 DK103184 (SSC)
NIH/NIDDK R01 DK115574 (SSC), NIH/NIDDK F32 DK121454 (JM)
NIH/NIDDK T32 DK108741 (GW)